Skip to main content

Home/ Vitamin D/ Group items tagged prostate_cancer 1.25(OH)2D

Rss Feed Group items tagged

Matti Narkia

Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25... - 0 views

  •  
    Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk.
    Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E.
    Prostate. 2007 Jun 15;67(9):911-23.
    PMID: 17440943
    DOI: 10.1002/pros.20570

    RESULTS
    No association was found between these SNPs or their associated haplotypes and all PC subtypes except that haplotype 2 (A-f-b) with Cdx2 A, Fok1 f, and Bsm1 b alleles and haplotype 3 (A-F-B) with Cdx2 A, Fok1 F and Bsm1 B alleles compared to the most common haplotype (A-F-b), were associated with reduced risk of aggressive PC (high stage or Gleason sum 7; P = 0.02), both with two alleles suspected of being low risk. Carriers of the variant Cdx2 A allele who were deficient in plasma 25-hydroxyvitamin D (15 ng/ml) compared to non-carriers with normal 25-hydroxyvitamin D, had a lower risk of total and poorly differentiated PCs (Gleason sum 7) (P for interaction = 0.02 and 0.04, respectively). Plasma 1,25-dihydroxyvitamin D deficiency (26 pg/ml) was associated with a threefold risk of poorly differentiated PC (P for interaction = 0.01) when comparing carriers of the Cdx2 A allele to non-carriers with normal 1,25-dihydroxyvitamin D.

    CONCLUSION
    In this population of men, none of the VDR polymorphisms studied was associated with susceptibility to PC.

    Carriers of the variant Cdx2 A allele with low plasma 25-hydroxyvitamin D may experience a reduction in risk of total and poorly differentiated prostate cancers compared to non-carriers with adequate 25-hydroxyvitamin D.
Matti Narkia

Vitamin D and Intervention Trials in Prostate Cancer: From Theory to Therapy - 0 views

  •  
    Vitamin D and intervention trials in prostate cancer: from theory to therapy.
    Schwartz GG.
    Ann Epidemiol. 2009 Feb;19(2):96-102. Epub 2008 Jul 10.
    PMID: 18619854
    doi:10.1016/j.annepidem.2008.03.007

    This suggests that whereas vitamin D (e.g., cholecalciferol) might prevent prostate cancer, existing prostate tumors likely would require treatment with 1,25(OH)(2)D and/or its analogs. The major obstacle to the use of 1,25(OH)(2)D in patients therapeutically is the risk of hypercalcemia. Several maneuvers to reduce this risk, including pulse dosing and the use of less calcemic 1,25(OH)(2)D analogs, have been explored in Phase I-III clinical trials. Once merely a promise, vitamin D-based therapies for prostate cancer may soon be medical practice.
Matti Narkia

Vitamin D and cancer Ali MM, Vaidya V - J Can Res Ther 2007 Oct-Dec - 0 views

  •  
    Vitamin D and cancer.
    Ali MM, Vaidya V.
    J Cancer Res Ther. 2007 Oct-Dec;3(4):225-30. Review.
    PMID: 18270398
    DOI: 10.4103/0973-1482.38998
1 - 3 of 3
Showing 20 items per page